Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY posts Q2'23 Financials & mBC intent

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 15, 2023 9:29pm

154 Views

Post# 35590212

RE:RE:RE:RE:RE:RE:RE:RE:ONCY posts Q2'23 Financials & mBC intent

HER2-low status is more frequent in HR+ than HR- breast cancer.

HER2-low status was found to be associated with better prognostic pathological tumor characteristics compared with HER2-negative, both in HR-positive and HR-negative tumors.

Among HR-negative tumors, HER2-low cancers are less often “basal like” when classified by the PAM50 gene array⁶⁰ compared to HER2-negative tumors, and in another study on HR-negative tumors, HER2-low status was more frequently seen in low-grade tumors (35% vs 18%) and in tumors with apocrine IHC markers (57% vs 36%) compared to HER2-negative tumors.

In patients with metastatic breast cancer, HER2-low status is more often found in HR-positive disease. When adjusted to other variables such as ER expression, visceral disease and age, patients with HER2-low metastatic BC were found to have a slightly better prognosis than those with HER2 -negative status in a study involving more than 15,000 patients diagnosed between the years 2000–2015 (HR 0.95, CI 0.91–0.99; P = 0.02).

Categorizing breast cancers as “HER2-low” carries inherent challenges,⁹⁷ and only a 26% concordance rate was found between 18 pathologists in designating breast tumors as HER2+1 or HER2-negative,⁹⁸ questioning the accuracy of the HER2-low diagnosis.

Results from ONCYs BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71% reduction in risk of disease progression.

https://www.oncolyticsbiotech.com/press-releases/detail/607/oncolytics-biotech-reports-second-quarter-2023-financial

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract